Tokyo, Oct. 5 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059286) titled 'Pharmacokinetics/pharmacodynamics/genome pharmacology study of the antibody-drug conjugate Sacituzumab Govitecan: multi-institutional prospective observational trial' on Oct. 4.
Study Type:
Observational
Primary Sponsor:
Institute - Keio University
Condition:
Condition - Triple Negative Breast Cancer (TNBC)
Classification by malignancy - Malignancy
Genomic information - YES
Objective:
Narrative objectives1 - To investigate whether there are differences in the incidence of adverse events and drug blood concentrations between patients with unresectable or recurrent triple-negative breast cancer who received Sacituzu...